Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | IKBKB | O14920 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 4/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12138690 | 0.81 | CHEK1 (0.37) | CYP3A4BRD4 | |
| SCHEMBL1359862 | 0.80 | MCL1 (0.39) | CYP3A4BRD4KDM4E | |
| SCHEMBL1971648 | 0.79 | KDM4E (0.46) | BRD4KDM4E | |
| SCHEMBL2128919 | 0.77 | CYP3A4 (0.52) | CYP3A4IKBKBBTKABL1CHUK | |
| SCHEMBL1359500 | 0.76 | CYP3A4 (0.37) | CYP3A4BRD4 | |
| SCHEMBL1988090 | 0.76 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL1359503 | 0.74 | CYP3A4 (0.37) | CYP3A4BRD4 | |
| SCHEMBL1358987 | 0.74 | CYP3A4 (0.40) | CYP3A4BRD4KDM4EABL1 | |
| SCHEMBL1359362 | 0.70 | GSK3B (0.40) | CYP3A4IKBKBABL1CHUK | |
| SCHEMBL3342848 | 0.70 | NPC1 (0.41) | BRD4IKBKBKDM4EBTKCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | claimed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CYP3A4 713/4885BRD4 1086/4885IKBKB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.